Patient description: A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow: A wellbeing, well-nourished man, non-icteric, cooperative and alert Weight: 73 kg Height: 177 BP: 120/80 HR: 90/min RR: 22/min Hgb: 13 g/dl WBC: 8000 /mm3 (Neutrophil: 2700/mm3) Plt: 300000 /ml AST: 40 U/L ALT: 56 U/L Alk P: 147 U/L Bill total: 1.2 mg/dl ESR: 120 mm/hr MPO-ANCA: 153 EU

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Perianal Warts ≥18 years of age 2. Diagnosed with perianal condyloma by primary clinician 3. HIV-infected, may be on or off of antiretroviral therapy. Enrolment of subjects on HAART will be restricted to those individuals for whom an alternative regimen can reasonably be constructed in case of failure. 4. Negative reaction to intradermal test with ciprofloxacin (a fluoroquinolone antibiotic) 5. Any CD4 count will be considered appropriate for study 6. Blood WBC > 2.0x103/mm3 and absolute neutrophils count > 500 7. Blood hemoglobin > 10.0 g/dL 8. Blood platelet count > 50x103/mm3 9. Serum total bilirubin < 6.0 mg/dL (participants taking atazanavir-based ARV regimens may have elevated total bilirubin but are generally < 6) 10. Blood aspartate aminotransferase (AST) < 100 U/L (<2 ULN) 11. Blood alanine aminotransferase (ALT) < 130 U/L (<2 ULN) 12. Serum creatinine < 1.5 mg/dL 13. ECOG performance status < 3 14. If a subject is of reproductive potential he/she and her/his sexual partner MUST be willing and able to utilize highly effective methods of contraception (e.g., birth control pill, barrier methods with spermicide as applicable) for the duration of the study including the study follow-up period. 15. Subjects must be willing to refrain from anal sex, douching and use of enemas prior to scheduled Pap smears  Anal cancer (current or history of) 2. Inability to attend study visits 3. Participation in any other drug study 4. History of asthma 5. History of CHF and/or cardiac support for arrhythmia or on chronic cardiac medication or has other chronic or acute cardiac ailments (e.g., or abnormal EKG at Baseline) 6. History of organ transplantation or requiring chronic administration of immune suppressive drugs in the last 6 months 7. For women, neither pregnant nor lactating 8. In the opinion of the Primary Investigator, the subject may not be able to tolerate the study treatment regimen 9. Subjects who are currently using or have recently within past 3 months) been treated with immunomodulators (e.g., Interferon-α) 10. Subjects with active infections including sexually transmitted diseases (e.g., N. gonorrhea, C. trachomatis, H. ducreyi, T. pallidum) 11. History of allergic reaction to fluoroquinolone antibiotics (e.g., ciprofloxacin, ofloxacin)